Comparing Innovation Spending: Zoetis Inc. and Ultragenyx Pharmaceutical Inc.

R&D Spending: Ultragenyx vs. Zoetis Over a Decade

__timestampUltragenyx Pharmaceutical Inc.Zoetis Inc.
Wednesday, January 1, 201445967000396000000
Thursday, January 1, 2015114737000364000000
Friday, January 1, 2016183204000376000000
Sunday, January 1, 2017231644000382000000
Monday, January 1, 2018293998000432000000
Tuesday, January 1, 2019357355000457000000
Wednesday, January 1, 2020412084000463000000
Friday, January 1, 2021497153000508000000
Saturday, January 1, 2022705789000539000000
Sunday, January 1, 2023648449000614000000
Monday, January 1, 2024686000000
Loading chart...

Unleashing insights

Innovation Spending: A Tale of Two Companies

In the ever-evolving landscape of pharmaceuticals and animal health, innovation is the key to staying ahead. Over the past decade, Ultragenyx Pharmaceutical Inc. and Zoetis Inc. have demonstrated contrasting approaches to research and development (R&D) spending. From 2014 to 2023, Ultragenyx increased its R&D expenses by over 1,300%, peaking in 2022 with a staggering 705 million dollars. This reflects their aggressive pursuit of groundbreaking therapies. Meanwhile, Zoetis, a leader in animal health, maintained a steady growth in R&D, with a 55% increase over the same period, reaching 614 million dollars in 2023. This consistent investment underscores their commitment to innovation in veterinary medicine. As these companies continue to invest in R&D, their strategies highlight the diverse paths to success in the pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025